Literature DB >> 21465972

Comparison of in vitro efficacy of linezolid and vancomycin by determining their minimum inhibitory concentrations against methicillin resistant Staphylococcus aureus (MRSA).

Fatima Kaleem1, Javaid Usman, Ali Khalid, Afreenish Hassan, Maria Omair.   

Abstract

OBJECTIVES: To compare the in vitro activities of vancomycin and linezolid against methicillin resistant Staphyloccus aureus in our set up to help in formulating a better empirical treatment and reduce the emergence of vancomycin resistant Staphylococcus aureus.
METHODS: The study was conducted over a period of 6 months (1st July 2009-31st Dec 2009). Fifty Methicillin resistant Staphylococcus aureus isolated from the clinical isolates of Military Hospital Rawalpindi were subjected to the determination of Minimum inhibitory concentrations of linezolid and vancomycin using E-strips.
RESULTS: All the isolated organisms were uniformly susceptible to both the antibiotics. Vancomycin showed higher minimum inhibitory concentrations (MICs) as compared to linezolid MICs.
CONCLUSION: This study suggests that linezolid and vancomycin have similar in vitro efficacy for methicillin resistant Staphyloccus aureus infections.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21465972

Source DB:  PubMed          Journal:  J Pak Med Assoc        ISSN: 0030-9982            Impact factor:   0.781


  2 in total

1.  Comparison of In-vitro Activities of Linezolid and Vancomycin against Staphylococcus aureus Isolated from A Tertiary Care Hospital.

Authors:  Sachin Kishore; Deepika Verma; Me Siddique
Journal:  J Clin Diagn Res       Date:  2014-05-15

2.  Staphylococcal Cassette Chromosome mec Typing and Multilocus Variable Number Tandem Repeat Analysis of Methicillin Resistant Staphylococcus aureus Clinical Isolates with Vancomycin Creep Phenomenon.

Authors:  Faiqa Arshad; Sidrah Saleem; Romeeza Tahir; Shah Jahan; Kokab Jabeen; Aneela Khawaja; Zille Huma; Muhammad Roman; Faheem Shahzad
Journal:  Infect Drug Resist       Date:  2022-07-25       Impact factor: 4.177

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.